Issued 2026-08-13 at $6.85 · now $6.49 (2026-08-13, −5.3% since)
Based on its own history, a month from the 2026-08-13 close, PGEN has typically landed between $4.83 and $9.41 — a range of −29.5% to +37.3% from the issuance price $6.85.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
3,251 overlapping 1 month windows · 2013-08-08 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($6.85) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where PGEN has typically landed a month from the 2026-08-13 close of $6.85 — the range is history, not a prediction.
- now $6.49 (-5.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.91 (+0.9%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.93–$7.89
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.83–$9.41
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-14 | −65.8% | −65.8% | +10.8% |
| 2020-02-18 | −63.1% | −67.0% | +7.0% |
| 2020-02-13 | −59.9% | −59.9% | +22.2% |
| 3 best | |||
| 2025-07-29 | +192.4% | +0.0% | +192.4% |
| 2025-08-01 | +185.0% | +0.0% | +185.0% |
| 2025-08-04 | +169.9% | −1.1% | +170.5% |
3,251 overlapping windows · 2013-08-08 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-11-11 — Trial primary completion: Phase 2 primary completion: PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~13 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.